Catalent

67 articles about Catalent

• Catalent Provides Business Update and Names Ricky Hopson as Interim Chief Financial Officer

  4/14/2023

  Catalent, Inc. today announced a business update.

• Catalent, Inc. to Present at March Investor Conferences

  3/9/2023

  Catalent, Inc. today announced that members of its executive leadership team will participate at two upcoming investor conferences.

• Catalent Publishes Fourth Annual Corporate Responsibility Report Highlighting Achievements While Providing New Record Number of Patient Treatments

  2/28/2023

  Catalent, Inc., the leader in enabling the development and supply of better treatments for patients worldwide, published its fourth Corporate Responsibility Report for its fiscal year 2022, which ended June 30, 2022.

• Catalent, Inc. Reports Second Quarter Fiscal 2023 Results

  2/7/2023

  Catalent, Inc. (NYSE: CTLT), the global leader in enabling pharma, biotech, and consumer health partners to optimize development, launch, and supply of better patient treatments across multiple modalities, today announced financial results for the second quarter of fiscal 2023, which ended December 31, 2022.

• Catalent, Inc. Announces Second Quarter Fiscal Year 2023 Earnings Conference Webcast

  1/20/2023

  Catalent, Inc. today announced that it will release financial results for the second quarter of fiscal year 2023 ended December 31, 2022, before the market open on Tuesday, February 7, 2023.

• Catalent Appoints Ricardo Zayas as North American Biologics Operations Leader

  1/17/2023

  Catalent, Inc. today announced the appointment of Ricardo Zayas as Senior Vice President, Operations, Biologics North America.

• Avantor® and Catalent Enter into Multi-Year Supply and Services Agreement

  1/9/2023

  Avantor, Inc. today announced that it has entered into a multi-year supply and services agreement with Catalent, Inc.

• Sarepta and Catalent Expand Strategic Manufacturing Partnership With Commercial Supply Agreement for Duchenne Muscular Dystrophy Gene Therapy Candidate

  1/5/2023

  Catalent, Inc. and Sarepta Therapeutics, Inc. today announced the signing of a commercial supply agreement for Catalent to manufacture delandistrogene moxeparvovec (SRP-9001), Sarepta’s most advanced gene therapy candidate for the treatment of Duchenne muscular dystrophy (DMD).

• Catalent Announces Changes to its Board of Directors - December 19, 2022

  12/19/2022

  Catalent, Inc. today announced that current board member and lead independent director J. Martin (“Marty”) Carroll has been unanimously selected by its Board of Directors to succeed John Chiminski and serve as Chair following Mr. Chiminski’s retirement.

• Exelixis and Catalent Enter into New License Agreement for Three Antibody-Drug Conjugate Programs with the Potential to Accelerate Exelixis’ Biologics Pipeline

  11/3/2022

  Exelixis, Inc. (Nasdaq: EXEL) and Catalent, Inc. (NYSE: CTLT) today announced a new license agreement under which Catalent’s Redwood Bioscience subsidiary will grant Exelixis an exclusive license to three target programs with lead antibody and/or ADC candidates.

• Catalent, Inc. Reports First Quarter Fiscal 2023 Results

  11/1/2022

  Catalent, Inc. (NYSE: CTLT), the global leader in enabling pharma, biotech, and consumer health partners to optimize development, launch, and supply of better patient treatments across multiple modalities, today announced financial results for the first quarter of fiscal 2023, which ended September 30, 2022.

• Catalent, Inc. Announces First Quarter Fiscal Year 2023 Earnings Conference Webcast

  10/17/2022

  Catalent, Inc. announced that it will release financial results for the first quarter of fiscal year 2023 ended September 30, 2022, before the market open on Tuesday, November 1, 2022.

• Catalent, Inc. to Present at September 2022 Investor Conferences

  9/8/2022

  Catalent, Inc. announced that members of its executive leadership team will participate at two upcoming investor conferences.

• Catalent, Inc. Reports Fourth Quarter Fiscal 2022 Results

  8/29/2022

  Catalent, Inc. today announced financial results for the fourth quarter of fiscal 2022, which ended June 30, 2022.

• Catalent to Acquire Metrics Contract Services for $475 Million to Expand High-Potent Capabilities and Oral Development and Manufacturing Capacity

  8/9/2022

  Catalent, Inc. announced that it has reached an agreement to acquire Metrics Contract Services, a full-service specialty Contract Development and Manufacturing Organization with a facility in Greenville, North Carolina, for $475 million from Mayne Pharma Group Limited .

• Catalent, Inc. Announces Fourth Quarter Fiscal Year 2022 Earnings Conference Webcast

  8/5/2022

  Catalent today announced that it will release financial results for the fourth quarter of fiscal year 2022 ended June 30, 2022, before the market open on Monday, August 29, 2022.

• Catalent Announces New Operating Structure

  7/5/2022

  Company Consolidates from Four Reporting Segments to Two, One Focusing on Biologics and the Other on Pharmaceuticals and Consumer Health.

• Catalent, Inc. to Present at June Investor Conferences

  5/27/2022

  Catalent, the global leader in enabling biopharma, cell, gene, and consumer health partners to optimize development, launch, and supply of better patient treatments across multiple modalities, today announced that members of its executive leadership team will present at two upcoming investor conferences.

• Catalent, Inc. Reports Third Quarter Fiscal 2022 Results

  5/3/2022

  Catalent, Inc. today announced financial results for the third quarter of fiscal 2022, which ended March 31, 2022.

• ERYTECH Sells U.S. Manufacturing Facility and Enters Long-Term Supply Agreement with Catalent

  4/25/2022

  ERYTECH Pharma announced the sale of its U.S. manufacturing facility toCatalent, a leading contract development and manufacturing organization in advanced therapies.